Self-Efficacy and Professional Pleasure of Social Welfare and Tribal Welfare Residential Secondary School Teachers: An Investigation

The present investigation is to make a probe into the relationship between Teacher Self-Efficacy and Professional Pleasure among Social Welfare and Tribal Welfare Residential Secondary School Teachers (N = 143), besides testing whether the correlations obtained for the comparable sample differ significantly and concludes that both the aspects are significant statistically. In respect of Teacher Self-efficacy, the variables like Sex, Age, Qualification and Experience are found statistically corroborated. In respect of Professional Pleasure all the variables viz., Sex, Locality, Age, Marital Status, Qualification, Experience and Type of Institution are statistically significant. Further, Teacher Self-efficacy and Professional Pleasure are independent but they are inter-dependent. The investigation shows that there is significance of relationship between the Dimensions of Teacher Self-efficacy and Professional Pleasure of the Teachers. The area wise means in merit order of Teacher Self-efficacy is – Vicarious experience, Mastery experience, Physiological and Psychological experience and social experience, while the mean value of dimension wise of Teachers Professional Pleasure in merit order is – Personal, Professional, Social and Intellectual aspects

EMERGING TRENDS IN PATIENT COUNSELLING: CURRENT SCENARIO

Objective: To evaluate the impact of patient counselling in terms of knowledge, attitudes and practices (KAP) outcomes among retail and hospital pharmacist in Satara and Sanagli district.Methods: A cross-sectional survey was conducted on knowledge, attitudes and practices of patient counselling adopted by retail and hospital pharmacists from different areas of Satara and Sangali district. A specially designed questionnaire was used for data collection. Total 190 respondents were analyzed for the study.Results: The highlighting result of the survey based project revealed that almost all retail as well as hospital pharmacists were practicing patient counselling without any charges and there is necessity of separate patient counselling cabinet. Pharmacist was lacking in adopting modern techniques, aids for counselling and 20% only attended patient counselling course (PCC) by Maharashtra State Pharmacy Council (MSPC).Conclusion: KAP study revealed the positive attitude, knowledge and existence of patient counselling practices but not done in an appropriate manner. Step should be taken by authorities, pharmacist and the patient to make counselling more effective.Â

Stability Studies of Crude Plant Material of Bacopa monnieri and Its Effect on Free Radical Scavenging Activity

Stability study of the crude plant material of Bacopa monnieri has been carried out as per ICH guidelines and its effect on free radical scavenging activity was studied by DPPH, ABTS radical scavenging assays and Deoxyribose degradation assay. The dried whole plant material of B. monnieri was kept in stability chambers at 40°C and 75% relative humidity in case of accelerated studies and at 30°C and 65% relative humidity for long term studies. Real time studies samples were stored at room temperature. Samples were taken out at periodic intervals, extracted in methanol to observe the HPTLC profiles and to study free radical scavenging activity. Results of antioxidant assays indicated that the samples of long term studies showed better antioxidant activity than the samples of accelerated and real time studies. Key words: Brahmi; accelerated study; long term study; real time study; free radical scavenging activity Abbreviations: BM: Bacopa monnieri; AS: Accelerated studies; LS: Long term studies; RT Real time studiesPratibha Srivastava et al. Stability Studies of Crude Plant Material of Bacopa monnieri and Its Effect on Free Radical Scavenging Activity. J Phytol 2/8 (2010) 103-109

Some Uses and Potentials of Qualitative Methods in Planning

Planners use methods borrowed from many disciplines. These are usually modified and adapted to meet planner's needs to acquire and sift through many diverse information sources helpful in dealing with complex problems. The quantitative methods which planners use are well known, well established in practice, and acknowledged by most as tools of the planners' trade. In contrast to this, most planners also use qualitative methods but these are rarely explicitly acknowledged.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68912/2/10.1177_0739456X8600600110.pd

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Background: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy. Methods: This randomised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as first-line treatment for patients with newly diagnosed focal epilepsy. Adult and paediatric neurology services across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked focal seizures. Participants were randomly allocated (1:1:1) using a minimisation programme with a random element utilising factor to receive lamotrigine, levetiracetam, or zonisamide. Participants and investigators were not masked and were aware of treatment allocation. SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. Anti-seizure medications were taken orally and for participants aged 12 years or older the initial advised maintenance doses were lamotrigine 50 mg (morning) and 100 mg (evening), levetiracetam 500 mg twice per day, and zonisamide 100 mg twice per day. For children aged between 5 and 12 years the initial daily maintenance doses advised were lamotrigine 1·5 mg/kg twice per day, levetiracetam 20 mg/kg twice per day, and zonisamide 2·5 mg/kg twice per day. All participants were included in the intention-to-treat (ITT) analysis. The per-protocol (PP) analysis excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analysis included all participants who received one dose of any study drug. The non-inferiority limit was a hazard ratio (HR) of 1·329, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on lamotrigine. The trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64). Findings: 990 participants were recruited between May 2, 2013, and June 20, 2017, and followed up for a further 2 years. Patients were randomly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328). The ITT analysis included all participants and the PP analysis included 324 participants randomly assigned to lamotrigine, 320 participants randomly assigned to levetiracetam, and 315 participants randomly assigned to zonisamide. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission versus lamotrigine (HR 1·18; 97·5% CI 0·95–1·47) but zonisamide did meet the criteria for non-inferiority in the ITT analysis versus lamotrigine (1·03; 0·83–1·28). The PP analysis showed that 12-month remission was superior with lamotrigine than both levetiracetam (HR 1·32 [97·5% CI 1·05 to 1·66]) and zonisamide (HR 1·37 [1·08–1·73]). There were 37 deaths during the trial. Adverse reactions were reported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zonisamide. Lamotrigine was superior in the cost-utility analysis, with a higher net health benefit of 1·403 QALYs (97·5% central range 1·319–1·458) compared with 1·222 (1·110–1·283) for levetiracetam and 1·232 (1·112, 1·307) for zonisamide at a cost-effectiveness threshold of £20 000 per QALY. Cost-effectiveness was based on differences between treatment groups in costs and QALYs. Interpretation: These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy. Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials. Funding: National Institute for Health Research Health Technology Assessment programme

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Background: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly prescribed for these patient populations despite scarcity of evidence of clinical effectiveness or cost-effectiveness. We aimed to compare the long-term clinical effectiveness and cost-effectiveness of levetiracetam compared with valproate in participants with newly diagnosed generalised or unclassifiable epilepsy. Methods: We did an open-label, randomised controlled trial to compare levetiracetam with valproate as first-line treatment for patients with generalised or unclassified epilepsy. Adult and paediatric neurology services (69 centres overall) across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked generalised or unclassifiable seizures. Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation programme with a random element utilising factors. Participants and investigators were aware of treatment allocation. For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5–12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate and 40 mg/kg for levetiracetam. All drugs were administered orally. SANAD II was designed to assess the non-inferiority of levetiracetam compared with valproate for the primary outcome time to 12-month remission. The non-inferiority limit was a hazard ratio (HR) of 1·314, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on valproate. All participants were included in the intention-to-treat (ITT) analysis. Per-protocol (PP) analyses excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analyses included all participants who received one dose of any study drug. This trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64). Findings: 520 participants were recruited between April 30, 2013, and Aug 2, 2016, and followed up for a further 2 years. 260 participants were randomly allocated to receive levetiracetam and 260 participants to receive valproate. The ITT analysis included all participants and the PP analysis included 255 participants randomly allocated to valproate and 254 randomly allocated to levetiracetam. Median age of participants was 13·9 years (range 5·0–94·4), 65% were male and 35% were female, 397 participants had generalised epilepsy, and 123 unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission (HR 1·19 [95% CI 0·96–1·47]); non-inferiority margin 1·314. The PP analysis showed that the 12-month remission was superior with valproate than with levetiracetam. There were two deaths, one in each group, that were unrelated to trial treatments. Adverse reactions were reported by 96 (37%) participants randomly assigned to valproate and 107 (42%) participants randomly assigned to levetiracetam. Levetiracetam was dominated by valproate in the cost-utility analysis, with a negative incremental net health benefit of −0·040 (95% central range −0·175 to 0·037) and a probability of 0·17 of being cost-effectiveness at a threshold of £20 000 per quality-adjusted life-year. Cost-effectiveness was based on differences between treatment groups in costs and quality-adjusted life-years. Interpretation: Compared with valproate, levetiracetam was found to be neither clinically effective nor cost-effective. For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding valproate. Funding: National Institute for Health Research Health Technology Assessment Programme

Studies on uranyl alkali silicate glasses

This article does not have an abstract

Sertoli cell tumor arising in a cryptorchid testis presenting as a content of inguinal hernial sac

Sertoli cell tumors (SCTs) are rare tumors accounting for <1% of all testicular tumors. Here, we report a rare case of SCT in a 60-year-old man presenting as a painless swelling in the right groin since childhood. Clinically, he presented with right-sided inguinal hernia with absence of the right testis. He had normal left testis and had no gynecomastia or infertility. The specimen of hernial sac showed testis with a 1.6 cm × 1.5 cm nodular mass having gray tan-cut surface. Histopathologically, the testis showed atrophy and the nodular portion showed tumor cells arranged in tubular and microcystic pattern, with no solid pattern or necrosis. The diagnosis of SCT was confirmed with immunohistochemical staining for inhibin which showed fine granular cytoplasmic positivity. Cryptorchid testis having SCT and presenting as a content of inguinal hernia is a rare occurrence

IN VITRO PLASMID CURING ACTIVITY OF AQUEOUS EXTRACT OF TERMINALIA CHEBULA FRUIT AGAINST PLASMIDS OF BACILLUS SUBTILIS AND SHIGELLA SONNEI

Objective: The aim of this investigation was to evaluate in vitro plasmid curing activity of the aqueous extract from Terminalia chebula fruit against multi-drug resistance bacteria.Methods: The aqueous extract of Terminalia chebula fruit was prepared in citrate phosphate buffer, pH 6.8. The extract was partially purified through gel chromatography. Antibacterial and antiplasmid activity against Salmonella typhi, Bacillus subtilis, Escherichia coli and Shigella sonnei was checked using the broth dilution method. The contents of crude extract were estimated.Results: The crude extracts exhibited anti plasmid activity against plasmids of B. subtilis and Sh. sonnei. Loss of plasmid band was confirmed by agarose gel electrophoresis. The curing efficiency of aqueous extract was found to be 100% and 44% against plasmids of B. subtilis (pUB110) and Sh. sonnei(pARI-815) respectively. The results were compared with conventional curing agent such as ethidium bromide and acridine.Conclusion: The aqueous extract of T. chebula fruit has the potential to inhibit growth of strains which are resistant to many antibiotics. Results could provide new insight into the treatment of infectious diseases which are facing limitation of antibiotics.Â